News Releases

- Darovasertib monotherapy results in 57% 1-year Overall Survival (OS) Rate in predominantly 2L / 3L and heavily pre-treated (out to 7L / 8L) MUM patients, where historical 1-year OS Rate has been reported at 37%

- IDE397 demonstrates significant single-agent anti-tumor activity in a 40-plus MTAP-deletion PDX study, including tumor regressions, across major solid tumor types, such as NSCLC, gastric, esophageal, and bladder cancers (AACR 2021)

- Initiated Phase 1 clinical trial for IDE397, a potential best-in-class MAT2A inhibitor for patients having tumors with MTAP-deletion

- Targeting enrollment of approximately 40 patients in the IDE196 and binimetinib clinical combination Phase 1/2 study in MUM

‒ IDEAYA's inaugural Synthetic Lethality Investor Day is planned for April 20, 2021 with scientific presentations from IDEAYA and GSK scientific leaders, and several Key Opinion Leaders

- Dr. Susan L. Kelley was a former clinical development executive in oncology with Bayer and Bristol Myers Squibb, and led the development and regulatory approval of Nexavar®

‒ Targeting First-Patient-In for IDE397 Phase 1 study in Q1 2021, as a potential best-in-class MAT2A inhibitor for cancer patients harboring MTAP-deletion, which is prevalent in ~15% of all solid tumors

IDE397 is being developed as a potential best-in-class MAT2A inhibitor for MTAP-deletion, which is prevalent in approximately 15% of all solid tumors

- IDE397, a potential best-in-class MAT2A inhibitor for patients with solid tumors having MTAP deletion, targeting an IND-filing in December 2020

- The partnership with the Sellers Laboratory at the Broad Institute of MIT and Harvard will utilize the Broad CRISPR paralog screening platform for Synthetic Lethality target and biomarker discovery, including for IDEAYA's PARG program

- Established strategic partnership with GlaxoSmithKline on Synthetic Lethality programs MAT2A, Pol Theta and Werner Helicase

- Closing of Glaxo Group Equity Investment of $20 Million in IDEAYA at $15.00 per share

- 4 evaluable GNAQ/11 mutation skin melanoma patients enrolled in Stage 1 cohort with a 100% Disease Control Rate (excluding 1 non-evaluable) and 1 confirmed partial response by RECIST 1.1 guidelines

- Dr. Garret Hampton serves as President, Clinical Sequencing and Oncology at Thermo Fisher Scientific, and held leadership roles at Illumina and Genentech

- Partnership covers three IDEAYA Synthetic Lethality programs - MAT2A, Pol Theta and Werner Helicase, and will explore combinations between IDEAYA and GSK programs

Clinical combination of IDE196, a PKC inhibitor, and binimetinib, a MEK inhibitor, to be investigated in patients with solid tumors that harbor GNAQ or GNA11 hotspot mutations, including Metastatic Uveal Melanoma, Cutaneous Melanoma, and Colorectal Cancer

Chief Executive Officer Yujiro Hata will present key research highlights on Synthetic Lethality today, January 15, 2020, at 5:00 pm PT (8:00 pm ET) at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco

- Targeting initiation of Phase 2 single-arm potentially registration-enabling clinical trial in MUM in Q1 2020, potentially coinciding with Phase 2 introduction of tablet formulation

- Robust enrollment, with 27 total patients enrolled in the Phase 1 dose escalation portion, including 12 patients in MUM DLT cohorts, 14 patients in MUM overflow cohort, and 1 GNA11 cutaneous melanoma patient in non-MUM GNAQ/11 cohort

- Update on Phase 1 Dose-Escalation portion of ongoing Phase 1/2 clinical trial, with specific focus on dosing schema, patient enrollment, and safety data, to be presented at SMR on November 20, 2019

- Single-arm Phase 2 clinical trial may be adequate to support an NDA seeking Accelerated Approval for IDE196 monotherapy in metastatic uveal melanoma (MUM)

Dr. Paul Barsanti joins as Vice President, Head of Drug Discovery

- FDA feedback from End‑of‑Phase 1 meeting indicates IDEAYA's proposed single-arm Phase 2 clinical trial may be adequate to support an NDA seeking Accelerated Approval for IDE196 monotherapy in metastatic uveal melanoma (MUM)